Regulatory T-Cell Therapy for Graft-versus-host Disease
- PMID: 27722210
- PMCID: PMC5049884
Regulatory T-Cell Therapy for Graft-versus-host Disease
Abstract
Graft-versus-host disease (GVHD) is a significant cause of non-relapse mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Existing strategies to prevent and treat GVHD are incomplete, where a significant portion of allo-HCT recipients developed this complication. Despite this, one such therapy has emerged involving the use of regulatory T cells (Tregs) to control GVHD. The use of natural Tregs (nTregs) yielded positive pre-clinical results and are actively under investigation to reduce GVHD. However, broad application of this approach may require standardization of Treg expansion methods and dosing. Inducible Tregs (iTregs) can be seamlessly generated, but controversial pre-clinical findings and phenotype instability have hampered their translation into the clinic. Here, we review the current biological differences between nTregs and iTregs, as well as their effects on GVHD and graft-versus-leukemia (GVL) responses. We conclude by exploring the idea of combinational cellular therapies for the prevention of GVHD and preservation of GVL.
Keywords: Cellular therapy; Graft-versus-host disease (GVHD); iTregs; nTregs.
Figures
References
-
- Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281–285. - PubMed
-
- Fu J, Heinrichs J, Yu XZ. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) 2014;62:277–301. - PubMed
-
- Pasquini MC, Z X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides 2014
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources